News Column

Findings from Blood Center Has Provided New Data on Gene Therapy (Neutralizing antibodies against AAV2, AAV5 and AAV8 in healthy and HIV-1-infected...

September 9, 2014



Findings from Blood Center Has Provided New Data on Gene Therapy (Neutralizing antibodies against AAV2, AAV5 and AAV8 in healthy and HIV-1-infected subjects in China: implications for gene therapy using AAV vectors)

By a News Reporter-Staff News Editor at China Weekly News -- Current study results on Biotechnology have been published. According to news reporting originating in Beijing, People's Republic of China, by VerticalNews journalists, research stated, "Adeno-associated viruses (AAV) have attracted attention as potential vectors for gene therapy and vaccines against several diseases, including HIV-1 infection. However, the presence of neutralizing antibodies (NAbs) after natural AAV infections inhibits their transfection in re-exposed subjects."

The news reporters obtained a quote from the research from Blood Center, "To identify candidate AAV vectors for therapeutic or prophylactic HIV vaccines, NAbs against AAV2, AAV5 and AAV8 were screened in the sera of healthy individuals in China and 10 developed countries and an HIV-1-infected Chinese population. Seroprevalence was higher for AAV2 (96.6%) and AAV8 (82.0%) than for AAV5 (40.2%) in normal Chinese subjects. Among individuals seropositive for AAV5, >80% had low NAb titers (China than in developed countries (P

According to the news reporters, the research concluded: "Therefore, AAV5 exposure is low in healthy and HIV-1-infected populations Chinese individuals, and vectors based on AAV5 may be appropriate for human gene therapy or vaccines."

For more information on this research see: Neutralizing antibodies against AAV2, AAV5 and AAV8 in healthy and HIV-1-infected subjects in China: implications for gene therapy using AAV vectors. Gene Therapy, 2014;21(8):732-738. Gene Therapy can be contacted at: Nature Publishing Group, Macmillan Building, 4 Crinan St, London N1 9XW, England. (Nature Publishing Group - www.nature.com/; Gene Therapy - www.nature.com/gt/)

Our news correspondents report that additional information may be obtained by contacting Q. Liu, Beijing Blood Center, Beijing, People's Republic of China. Additional authors for this research include W. Huang, H. Zhang, Y. Wang, J. Zhao, A. Song, H. Xie, C. Zhao, D. Gao and Y. Wang.

Keywords for this news article include: Beijing, People's Republic of China, Asia, Acquired Immunodeficiency Syndrome, Asia, Bioengineering, Biological Products, Biotechnology, Blood Proteins, China, Gene Therapy, HIV Infections, HIV/AIDS, Immunoglobulins, Immunology, Neutralizing Antibodies, Pharmaceuticals, Primate Lentiviruses, RNA Viruses, Retroviridae, Serum Globulins, Vaccines, Vertebrate Viruses, Viral Sexually Transmitted Diseases, Virology

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: China Weekly News


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters